Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  pegylated liposomal doxorubicin hydrochloride
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 171 for your search:
Start Over
Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 to 90
Sponsor: Other
Protocol IDs: GEICAM 2001-01, NCT00128778
Combination Chemotherapy in Treating Older Patients With Solid Tumour,
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 75 and over
Sponsor: Other
Protocol IDs: CDR0000593133, GERCOR-OLD, EudraCT-2007004103-36, GERCOR-OLD07-SA07-1, NCT00664911
Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: GBG 66, 2011-000553-23, NCT01426880
Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: Other
Protocol IDs: DS 96-28, RPCI-DS-96-28, SEQUUS-30-38, NCI-G97-1241, NCT00002985
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: Any age
Sponsor: NCI, Other
Protocol IDs: GOG-0182, NCI-2012-02376, SWOG-G0182, CDR0000068467, ISRCTN41636183, MRC-ICON5, ECOG-G0182, U10CA027469, NCT00011986
A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR004579, DO04-23-006, NCT00097981
TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TLK286.3024, NCT00102973
Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR004117, DOXILMMY3001, 2004-001842-34, NCT00103506
An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR003448, ET743-OVA-301, 2004-005276-16, NCT00113607
Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CALYPSO, EudraCT 2004-04456-39, NCT00189553
Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CEPO906A2303, NCT00262990
MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 75 and under
Sponsor: Other
Protocol IDs: MITO-2, 2005-004453-98, NCT00326456
A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR004120, DOXILBCA3001, UCLA-0507099-01, JJPRD-DOXIL-BCA-3001, NCT00091442
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: CDR0000256331, S0200, U10CA032102, SWOG-S0200, NCT00043082
F511 Cream in Preventing Palmar-Plantar Erythrodysesthesia in Patients Receiving Doxorubicin Hydrochloride Liposome for Metastatic Breast Cancer
Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: SAKK 92/08, SWS-SAKK-92/08, EU-20978, CDR0000652808, NCT00992706
Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-03149, E1D96, U10CA021115, CDR0000066331, AMC-009, SWOG-E1D96, CPMC-IRB-9905, NCT00003350
Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)
Phase: Phase III
Type: Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 8109-002, EC-FV-06, NCT01170650
TRINOVA-2: Trebananib in Ovarian Cancer-2
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20060517, 2009-017946-30, ENGOT-ov-6, TRINOVA-2, NCT01281254
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LTS12674, 2011-006246-33, U1111-1127-0888, NCT01593228
The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071)
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P04445, NCT00266799
VX-853 in Treating Patients With Solid Tumors Who Are Receiving Liposomal Doxorubicin
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000065641, P30CA051008, GUMC-96007, VX-95-853-001, VX-GUMC-96007, NCI-V97-1275, NCT00004030
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: Any age
Sponsor: NCI, Other
Protocol IDs: CDR0000068042, CLB-59804, CALGB-59804, NCT00006029
Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000068331, P30CA016087, NYU-0012, ALZA-00-001-ii, NCI-G00-1878, NCT00006825
Start Over